Jill M Kolesar1, Marcia Pomplun2, Tom Havighurst3, Jeanne Stublaski2, Barbara Wollmer2, KyungMann Kim3, Joseph A Tangrea4, Howard L Parnes4, Margaret G House4, Jason Gee5, Edward Messing6, Howard H Bailey7. 1. School of Pharmacy, University of Wisconsin, Madison, WI, USA Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA jmkolesar@pharmacy.wisc.edu. 2. Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA. 3. Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA. 4. Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA. 5. Institute of Urology, Lahey Clinic Medical Center, Burlington, MA, USA. 6. University of Rochester Medical Center, Rochester, NY, USA. 7. Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Abstract
BACKGROUND: The isoflavone genistein, a natural soy product with receptor tyrosine kinase-inhibiting activity, as well as phytoestrogenic and other potential anticarcinogenic effects, is being studied as an anticancer agent. Since isoflavones are commonly consumed in food products containing soy proteins, a method to control for baseline isoflavone consumption is needed. METHODS:HPLC was used to evaluate baseline plasma and urine concentrations of isoflavone in fifty-four participants with bladder cancer enrolled on a phase II chemoprevention study of G-2535. The soy food frequency questionnaire was used to assess participant's baseline soy intake. The association between baseline isoflavone concentrations and intakes for genistein and daidzein was assessed by the Spearman's rank correlation coefficient. RESULTS: The majority of participants had no detectable genistein or daidzein in plasma at baseline. The median and range of values were 0 (0-1480) nmol/L for genistein, and 0 (0-1260) nmol/L for daidzein. In urine, the median and range of values were 91.0 (0-9030) nmol/L for genistein and 623 (0-100,000) nmol/L for daidzein. The median and range of weekly estimated genistein intake was 0 (0-236) mg/wk; the median and range of weekly estimated daidzein intake was 0 (0-114) mg/wk. There was no relationship to soy intake as measured by the food frequency questionnaire and baseline isoflavone levels in plasma or urine and the Spearman's rank correlation coefficients were not significant. CONCLUSION: The soy food frequency questionnaire did not correlate with plasma or urine concentrations of either isoflavone. IMPACT: Alternative methods for controlling for soy consumption, including measuring plasma and urine concentrations, in isoflavone chemoprevention trials should be considered.
RCT Entities:
BACKGROUND: The isoflavonegenistein, a natural soy product with receptor tyrosine kinase-inhibiting activity, as well as phytoestrogenic and other potential anticarcinogenic effects, is being studied as an anticancer agent. Since isoflavones are commonly consumed in food products containing soy proteins, a method to control for baseline isoflavone consumption is needed. METHODS: HPLC was used to evaluate baseline plasma and urine concentrations of isoflavone in fifty-four participants with bladder cancer enrolled on a phase II chemoprevention study of G-2535. The soy food frequency questionnaire was used to assess participant's baseline soy intake. The association between baseline isoflavone concentrations and intakes for genistein and daidzein was assessed by the Spearman's rank correlation coefficient. RESULTS: The majority of participants had no detectable genistein or daidzein in plasma at baseline. The median and range of values were 0 (0-1480) nmol/L for genistein, and 0 (0-1260) nmol/L for daidzein. In urine, the median and range of values were 91.0 (0-9030) nmol/L for genistein and 623 (0-100,000) nmol/L for daidzein. The median and range of weekly estimated genistein intake was 0 (0-236) mg/wk; the median and range of weekly estimated daidzein intake was 0 (0-114) mg/wk. There was no relationship to soy intake as measured by the food frequency questionnaire and baseline isoflavone levels in plasma or urine and the Spearman's rank correlation coefficients were not significant. CONCLUSION: The soy food frequency questionnaire did not correlate with plasma or urine concentrations of either isoflavone. IMPACT: Alternative methods for controlling for soy consumption, including measuring plasma and urine concentrations, in isoflavone chemoprevention trials should be considered.
Authors: Cara L Frankenfeld; Ruth E Patterson; Neilann K Horner; Marian L Neuhouser; Heather E Skor; Thomas F Kalhorn; William N Howald; Johanna W Lampe Journal: Am J Clin Nutr Date: 2003-03 Impact factor: 7.045
Authors: Edward Messing; Jason R Gee; Daniel R Saltzstein; KyungMann Kim; Anthony diSant'Agnese; Jill Kolesar; Linda Harris; Adrienne Faerber; Thomas Havighurst; Jay M Young; Mitchell Efros; Robert H Getzenberg; Marcia A Wheeler; Joseph Tangrea; Howard Parnes; Margaret House; J Erik Busby; Raymond Hohl; Howard Bailey Journal: Cancer Prev Res (Phila) Date: 2012-01-31
Authors: Marilyn Tseng; Temitope Olufade; Mindy S Kurzer; Kristiina Wahala; Carolyn Y Fang; Yvonne T van der Schouw; Mary B Daly Journal: Nutr Cancer Date: 2008 Impact factor: 2.900